Sodium glucose co-transporter (SGLT) is one of the transporters responsible for the resorption of glucose, and inhibition of its activity can decrease the resorption of glucose. Human SGLT is mainly composed of SGLT1 and SGLT2. Due to the specific distribution and the high efficiency of SGLT2, SGLT2 inhibitor is a potential new strategy for treatment diabetes. Abundant animal experiments and clinical trails have found that SGLT2 inhibitor can greatly lower the blood glucose and help to lose weights. However, the current researches about SGLT2 inhibitor are still very limited both in depth and in broadness; problems concerning the safety, efficacy and indication of SGLT2 inhibitor still need to be further studied.